References: |
1. Weisberg, E., et al. "AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL." Br. J. Cancer 94:1765-1769 (2006). 2. Weisberg, E., et al. "Characterization of AMN-107, a selective inhibitor of native and mutant Bcr-Abl." Cancer Cell. 7:129-141 (2005). 3. O'Hare, T., et al. "In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants." Cancer Res. 65:4500-4505 (2005). 4. Golemovic, M., et al. "AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid Leukemia." Clin. Cancer Res. 11:4941-4947 (2005). 5. Verstovsek, S., et al. "Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells." Leuk. Res. 30:1499-1505 (2006). |